TABLE 4.
Frequency of inhibitory KIR, cognate HLA class I ligands, and activating KIR gene combinations in the control group and COVID-19 patients.
| Inhibitory KIR + HLA class I ligand + activating KIR | Hospitalized COVID-19 patients | ||||
|---|---|---|---|---|---|
| All patients n = 200 | Mild n = 93 | Severe n = 107 | Controls n = 195 | Comparisons: p-value, OR (95% CI) | |
| %F (N+) | %F (N+) | %F (N+) | %F (N+) | ||
| 3DL1+Bw4+ and 2DS1-2DS5- | 30.5 (61) | 31.2 (29) | 29.9 (32) | 41.5 (81) | AxC: 0.02, 0.62 (0.41–0.94); SxC: 0.047, 0.6 (0.36–1) |
| (3DL1+Bw4+)- and 2DS1+2DS5+ | 21.0 (42) | 14.0 (13) | 27.1 (29) | 13.3 (26) | AxC: 0.04, 1.73 (1.0–2.9); SxC: 0.0036, 2.4 (1.3–4.4); SxM: 0.025, 2.3 (1.1–4.7) |
| 3DL2+A3/11+ and 2DS1-2DS5- | 17.0 (34) | 21.5 (20) | 13.1 (14) | 22.1 (43) | |
| (3DL2+A3/11+)- and 2DS1+2DS5+ | 27.0 (54) | 22.6 (21) | 30.8 (33) | 17.4 (34) | AxC: 0.02, 1.75 (1.1–2.8); SxC: 0.008, 2.1 (1.2–3.7) |
| (3DL1+Bw4+)- and/or (3DL2+A3/11+)- 2DS1+2DS5+ | 15.0 (30) | 10.8 (10) | 18.7 (20) | 7.2 (14) | AxC: 0.02, 2.28 (1.17–4.45); SxC: 0.003, 2.97 (1.4–6.2) |
| (3DL1+Bw4+)- and (3DL2+A3/11+)- and 2DS1+2DS5+ | 33.5 (67) | 25.8 (24) | 40.2 (43) | 23.6 (46) | AxC: 0.03, 1.63 (1.04–2.53); SxC: 0.003, 2.2 (1.3–3.6); SxM: 0.03, 1.9 (1.05–3.53) |
| (3DL1+Bw4+)- and/or (3DL2+A3/11+)- and 2DL1+C2+ and 2DS1+2DS5+ | 7.5 (15) | 6.5 (6) | 8.4 (9) | 2.1 (4) | AxC: 0.02, 3.87 (1.26–11.88); SxC: 0.016, 4.4 (1.3–14.6) |
| (3DL1+Bw4+)- and/or (3DL2+A3/11+)- and 2DL1+C2+ and 2DS1-2DS5- | 8.5 (17) | 11.8 (11) | 5.6 (6) | 8.2 (16) | |
| (3DL1+Bw4+)- and (3DL2+A3/11+)- and 2DL1+C2+ and 2DS1+2DS5+ | 17.0 (34) | 15.1 (14) | 18.7 (20) | 9.7 (19) | AxC: 0.04, 1.90 (1.04–3.46); SxC: 0.03, 2.1 (1.1–4.2) |
| (3DL1+Bw4+)- and (3DL2+A3/11+)- and 2DL1+C2+ and 2DS1-2DS5- | 26.5 (53) | 31.2 (29) | 22.4 (24) | 26.7 (52) | |
Frequency (%F) of each genotype is expressed as a percentage and defined as the number of individuals having the genotype (N+) divided by the number of individuals studied (n) in the study group;OR, Odds ratio; CI, Confidence interval; Comparisons: AxC, all patients vs. controls, MxC, mild vs. controls, SxC, severe vs. controls, SxM, sever vs. mild.
Values shows significant difference are shown in bold.